182 related articles for article (PubMed ID: 29956623)
21. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
22. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
23. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
Wang R; Zhong C; Zhang C; Hua M; Ma D
Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
25. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
28. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.
Breccia M; Molica M; Alimena G
Leuk Res; 2014 Dec; 38(12):1392-8. PubMed ID: 25449685
[TBL] [Abstract][Full Text] [Related]
29. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
[TBL] [Abstract][Full Text] [Related]
30. Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status.
Huber L; Birk R; Rotter N; Aderhold C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2020 Feb; 40(2):825-835. PubMed ID: 32014925
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.
Ntanasis-Stathopoulos I; Fotopoulos G; Tzanninis IG; Kotteas EA
Cancer Invest; 2016 Aug; 34(7):313-39. PubMed ID: 27486869
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Fountas A; Diamantopoulos LN; Tsatsoulis A
Trends Endocrinol Metab; 2015 Nov; 26(11):643-656. PubMed ID: 26492832
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
36. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.
Yu JC; Lokker NA; Hollenbach S; Apatira M; Li J; Betz A; Sedlock D; Oda S; Nomoto Y; Matsuno K; Ide S; Tsukuda E; Giese NA
J Pharmacol Exp Ther; 2001 Sep; 298(3):1172-8. PubMed ID: 11504817
[TBL] [Abstract][Full Text] [Related]
38. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
40. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
Antoniu SA; Kolb MR
IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]